A new Alzheimer’s drug candidate demonstrated early promise in a clinical trial by reducing biomarkers linked to brain damage while maintaining a favorable safety profile. Results appeared in Nature Medicine and were presented as a late-breaking study at the 2026 Alzheimer’s Association International Conference (AAIC), held July 12-15 in London.
The phase 1b trial evaluated IBC-Ab002, an experimental anti-PD-L1 antibody developed by ImmunoBrain Checkpoint Inc., in patients with early-stage Alzheimer’s disease. The drug takes a different approach from existing treatments that focus on amyloid plaques or tau proteins. Instead, it temporarily modulates the peripheral immune system to potentially aid the brain’s repair processes.
Trial finds biomarker reductions, no major safety concerns
The study enrolled patients with early AD across 11 centers in the United Kingdom, Israel, and the Netherlands. Participants were randomly assigned to receive different doses of IBC-Ab002 or placebo and were followed for 48 weeks. Though the trial primarily assessed safety and tolerability, exploratory analyses showed reductions in cerebrospinal fluid biomarkers tied to neuronal and synaptic injury.
At the highest dose, most patients exhibited decreases in neurogranin, total tau, and phosphorylated tau 181 (p-tau181)—markers associated with synaptic dysfunction and neurodegeneration. The trial was not designed to prove clinical efficacy, so the biomarker changes do not confirm the drug slows cognitive decline.
“Our approach, the first of its kind, seeks to restore the immune system’s ability to protect and repair the brain,” said Michal Schwartz, PhD, scientific co-founder of ImmunoBrain Checkpoint and a professor at the Weizmann Institute of Science. “Curiosity-driven research that once questioned the long-standing belief that the brain operates independently of the immune system has led to a new understanding of neurodegenerative diseases.”
A different strategy for Alzheimer’s treatment
IBC-Ab002 is designed with a short half-life, enabling intermittent immune modulation rather than continuous treatment. This reduces risks tied to prolonged checkpoint inhibition, a known issue in cancer immunotherapy. The company’s method stems from research led by Schwartz, which examined how peripheral immune activity influences brain health.
Related: Challenging the status quo on human rights
Previous studies indicated the brain depends on immune support for repair, contradicting the traditional view of the central nervous system as isolated. The trial’s results support that idea, though the drug’s long-term effects remain uncertain.
This immune-based method contrasts with approved Alzheimer’s therapies like lecanemab and donanemab, which target amyloid plaques. While those drugs modestly slow cognitive decline, they do not address broader brain repair mechanisms. Developers of IBC-Ab002 suggest immune modulation could provide a complementary or alternative option, though clinical validation is still years away.
The trial had notable limitations. As a phase 1b study, it did not measure cognitive outcomes, and the biomarker results require confirmation in larger, longer trials. The company now plans the next phase of testing to determine whether the drug’s effects lead to meaningful clinical benefits.
“The findings offer early evidence of biological activity and justify further investigation,” the company said. “Larger randomized studies will be necessary to establish whether these biomarker changes translate into clinical improvements.”
If successful, the drug could provide new options for Alzheimer’s, a disease with few therapies that go beyond amyloid clearance. For now, IBC-Ab002 remains an experimental concept challenging long-held assumptions about the brain’s relationship with the immune system. Access to such treatments may face system restrictions as development progresses.